State Street SPDR S&P Biotech ETF
780 hedge funds and large institutions have $9.75B invested in State Street SPDR S&P Biotech ETF in 2024 Q1 according to their latest regulatory filings, with 129 funds opening new positions, 257 increasing their positions, 233 reducing their positions, and 83 closing their positions.
55% more first-time investments, than exits
New positions opened: 129 | Existing positions closed: 83
22% more capital invested
Capital invested by funds: $8.02B → $9.75B (+$1.73B)
20.35% more ownership
Funds ownership: 110.47% → 130.81% (+20%)
10% more repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 233
5% more funds holding
Funds holding: 745 → 780 (+35)
0% more funds holding in top 10
Funds holding in top 10: 23 → 23 (0)
43% less call options, than puts
Call options by funds: $2.25B | Put options by funds: $3.97B
Top Buyers
| 1 |
Citigroup
New York
|
+$437M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$382M |
| 3 |
JP Morgan Chase
New York
|
+$348M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$274M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$128M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$318M |
| 2 |
MCM
Moore Capital Management
New York
|
-$146M |
| 3 |
Twin Tree Management
Dallas,
Texas
|
-$65.3M |
| 4 |
Millennium Management
New York
|
-$64.2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$56.6M |
XBI Hedge Fund Activity: Q1 2024 in Review
780 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2024, worth a combined $9.75B — up 22% from $8.02B a quarter earlier.
Buyers outnumbered sellers: 129 funds opened new XBI positions and 83 closed out — a net gain of 46 holders — while 257 added to existing stakes and 233 trimmed.
The largest buyer was Citigroup, adding an estimated $437M. The largest seller was Morgan Stanley, cutting an estimated $318M.
- 780 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2024, up from 745 in Q4 2023.
- Funds reported $9.75B of State Street SPDR S&P Biotech ETF stock for Q1 2024, up 22% quarter-over-quarter.
- 129 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2024 and 83 closed out, a net change of +46 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2024 was Citigroup, an estimated $437M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2024 was Morgan Stanley, an estimated $318M sold.
Based on aggregated 13F filings for Q1 2024.